Overview

Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Status:
Unknown status

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicity of liposomal paclitaxel plus capecitabine in Chinese patients with advanced gastric carcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

Nanjing Sike Pharmaceutical Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Paclitaxel